Kinzalkomb (Hydrochlorothiazide, Telmisartan)

Hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, promoting diuresis and reducing plasma volume. Telmisartan selectively blocks the AT1 receptor, preventing angiotensin II‑mediated vasoconstriction and aldosterone release. The combined actions lower cardiac output and systemic vascular resistance, resulting in reduced blood pressure.

The appropriate dose of Kinzalkomb is determined by the prescribing clinician based on the patient’s blood‑pressure profile, renal function, and concomitant medications. Dosage adjustments may be required for special populations, and the medication should be taken exactly as directed on the prescription label.

Safety of Kinzalkomb in pregnancy has not been established, and it should be used only if the potential benefit justifies the potential risk to the fetus. Breastfeeding is not recommended because the active ingredients can be excreted in milk; alternative therapies should be considered.

To place an order, submit an enquiry on the Kinzalkomb product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with single‑agent therapy, Kinzalkomb offers the convenience of two complementary mechanisms in one tablet, which can improve adherence and provide synergistic blood‑pressure reduction. It is often preferred over separate prescriptions of a thiazide diuretic and an ARB when combination therapy is indicated, but choice depends on individual patient factors and tolerability.

Kinzalkomb tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiration date printed on the label.

Kinzalkomb is taken orally, usually once daily, with or without food, as directed by the prescribing physician. Swallow the tablet whole with a glass of water; do not crush or split the tablet unless specifically instructed by a healthcare professional.

The most serious risks include severe allergic reactions such as anaphylaxis, acute kidney injury, and hyperkalemia, which can be life‑threatening if not recognized promptly. Patients should be monitored for signs of rash, swelling, sudden loss of kidney function, or markedly elevated potassium levels and seek immediate medical attention if they occur.

Kinzalkomb is contraindicated in patients with known hypersensitivity to either hydrochlorothiazide or telmisartan, severe renal impairment, and in those taking aliskiren concomitantly if they have diabetes. Caution is also advised for individuals with hepatic dysfunction, electrolyte disturbances, or a history of angio‑edema. Clinicians must evaluate each patient’s medical history before prescribing.